Supplemental material
Journal of Medical Economics
Volume 23, 2020 - Issue 11
Open access
2,995
Views
3
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system
Rodrigo Shimabukuro Hoa Roche Diagnostics, São Paulo, BrazilCorrespondence[email protected]
, Mariana Mioti Sebastiãoa Roche Diagnostics, São Paulo, Brazil
, João Paulo Venezian de Carvalhob Roche Diagnostics LATAM, São Paulo, Brazil
, Tomás Nevesb Roche Diagnostics LATAM, São Paulo, Brazil
& Micha Nussbauma Roche Diagnostics, São Paulo, Brazil
Pages 1340-1344
|
Received 10 Aug 2020, Accepted 03 Sep 2020, Published online: 26 Sep 2020
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.